View Older Stories View More Recent Stories

Aug 30, 2021 07:55AM Eisai Announces New Executive Leadership Team at H3 Biomedicine
Aug 11, 2021 07:31PM FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)
Aug 5, 2021 07:55AM Eisai Inc. Announces the Appointment of Dr. Janna Hutz as President of the Eisai Center for Genetics Guided Dementia Discovery
Jul 29, 2021 04:30PM Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
Jul 22, 2021 07:32AM Eisai Alzheimer's Disease Pipeline Research, Including New Lecanemab (BAN2401) Data, to be Presented at 2021 Alzheimer's Association International Conference (AAIC)
Jun 28, 2021 07:55AM Eisai Inc. Announces the Appointment of Dr. Andree Amelsberg as Vice President, U.S. Medical Affairs, Oncology Business Group
Jun 23, 2021 04:07PM Eisai, Biogen (BIIB) Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 23, 2021 04:06PM Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 9, 2021 08:04AM Eisai to Present Latest DAYVIGO® (lemborexant) CIV Data at 35th Annual Virtual SLEEP 2021 Meeting
May 24, 2021 08:45AM Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer's Disease Detection and Services for Patients
May 18, 2021 08:34AM Eisai Announces Real-World Data on the Effectiveness of HALAVEN® (eribulin mesylate) for the Treatment of Patients with Metastatic Breast Cancer (mBC) Published in Advances in Therapy
May 17, 2021 08:08AM Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various Tumor Types
Apr 29, 2021 08:08AM Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer
Apr 16, 2021 11:53AM Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy
Mar 31, 2021 08:08AM Eisai And Advocacy Leaders Team Up To Launch Spot Her - An Initiative That Empowers Women To Help Spot The Signs Of Endometrial Cancer
Mar 10, 2021 08:08AM Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer
Mar 5, 2021 08:52AM Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data
Feb 2, 2021 02:39PM Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs
Feb 2, 2021 04:00AM Two Immigrants, One Unique Plan For A Biopharma
Jan 27, 2021 08:08AM Eisai to Present Investigational Data on LENVIMA® (lenvatinib) Based Combination Therapies in Renal Cell Carcinoma at the 2021 Genitourinary Cancers Symposium
Jan 20, 2021 07:55AM Dr. Richard Woodman Appointed Chief Clinical Officer of the Oncology Business Group at Eisai Inc.
Jan 11, 2021 08:08AM Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium
Dec 8, 2020 07:38AM #ThisIsMBC Perseverance Campaign from Eisai and METAvivor Captures the Joys, Difficulties and Realities Faced by People Living with Metastatic Breast Cancer
Dec 7, 2020 10:15AM Eisai Presents Long-Term Seizure Freedom And Real-World Data Related To Anti-Epileptic Drug FYCOMPA® At The AES 2020 Annual Meeting
Dec 1, 2020 12:21PM Eisai To Present New Seizure Freedom And Real-World Clinical Practice Data Evaluating FYCOMPA® Across Diverse Patient Types At Upcoming AES 2020 Annual Meeting
Nov 20, 2020 06:00PM Eisai Announces New Investigational Data from Study 211 Evaluating the Starting Dose of LENVIMA® (lenvatinib) in Differentiated Thyroid Cancer at ESMO Asia 2020
Nov 19, 2020 09:10PM Eisai to Present New Investigational Data on LENVIMA® (lenvatinib) in Thyroid Cancer and Osteosarcoma at ESMO Asia 2020
Nov 7, 2020 07:00AM Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA® (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020
Nov 5, 2020 07:00PM Eisai Announces Investigational Data Highlighting LENVIMA® (lenvatinib) Based Combination Therapy in Patients With Renal Cell Carcinoma at IKCS 2020
Nov 2, 2020 12:02PM Eisai to Present Latest Alzheimer's Disease Pipeline Research at Digital CTAD 2020, Including BAN2401, Anti-Microtubule Binding Region Tau Antibody, and Lemborexant Data
Sep 30, 2020 09:02AM Eisai Initiates Phase 3 MOMENTUM 1 Clinical Trial (Study 304) of Lorcaserin in Dravet Syndrome
Sep 22, 2020 07:10PM Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 10, 2020 07:30PM Eisai to Present New Data Highlighting KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and Eribulin Platform at ESMO 2020
Aug 28, 2020 11:31AM Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020
Aug 24, 2020 08:10AM Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO™ (lemborexant) CIV, at the SLEEP 2020 Virtual Conference
Aug 11, 2020 09:05AM Eisai Pharmaceuticals to Make the ON3 Next-Generation Life-Science and Lifestyle Campus its U.S. Headquarters
Aug 11, 2020 08:08AM Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer
Jul 24, 2020 08:46AM Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AAIC 2020, Including BAN2401 and Lemborexant Data and a Biomarker Symposium
Jul 13, 2020 07:20PM Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
Jul 8, 2020 07:30AM Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
Jun 1, 2020 08:05AM Eisai Announces U.S. Availability of DAYVIGO® (lemborexant) CIV, a New Treatment Option for Adults With Insomnia
May 29, 2020 08:35AM Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer a
May 13, 2020 07:44PM Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, including KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin mesylate)
Mar 19, 2020 02:45PM Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Feb 15, 2020 10:00AM Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Feb 10, 2020 06:48PM Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium
Feb 10, 2020 08:35AM METAvivor and Presenting Sponsor Eisai Inc. Team Up with AnaOno Intimates to Fearlessly Unite all Those Affected by Breast Cancer and Shine a Spotlight on Metastatic Breast Cancer during New York Fash
Feb 3, 2020 07:58AM Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Jan 21, 2020 05:27PM Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Dec 27, 2019 11:13AM Pivotal Phase 3 Study of DAYVIGO™ (lemborexant) for the Treatment of Insomnia Disorder Published in JAMA Network Open
View More Recent Stories View Older Stories